Oruka Therapeutics, Inc. (NASDAQ:ORKA – Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 8,971 shares of the company’s stock in a transaction dated Wednesday, February 12th. The shares were bought at an average cost of $11.86 per share, for a total transaction of $106,396.06. Following the acquisition, the insider now owns 4,044,684 shares in the company, valued at approximately $47,969,952.24. The trade was a 0.22 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Friday, February 14th, Venrock Healthcare Capital Par acquired 88,794 shares of Oruka Therapeutics stock. The shares were bought at an average price of $11.44 per share, for a total transaction of $1,015,803.36.
- On Monday, February 10th, Venrock Healthcare Capital Par bought 574 shares of Oruka Therapeutics stock. The stock was bought at an average cost of $10.90 per share, with a total value of $6,256.60.
Oruka Therapeutics Trading Down 9.2 %
ORKA stock opened at $9.56 on Friday. The company’s 50-day moving average is $14.49. The stock has a market cap of $334.59 million, a PE ratio of -1.53 and a beta of 0.77. Oruka Therapeutics, Inc. has a twelve month low of $9.53 and a twelve month high of $53.88.
Analysts Set New Price Targets
Get Our Latest Analysis on ORKA
Hedge Funds Weigh In On Oruka Therapeutics
Hedge funds have recently modified their holdings of the company. FMR LLC purchased a new position in shares of Oruka Therapeutics during the 3rd quarter valued at $114,763,000. RTW Investments LP bought a new stake in Oruka Therapeutics during the third quarter valued at about $45,359,000. Vanguard Group Inc. lifted its position in shares of Oruka Therapeutics by 4,161.2% in the fourth quarter. Vanguard Group Inc. now owns 1,610,651 shares of the company’s stock valued at $31,231,000 after acquiring an additional 1,572,853 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its stake in shares of Oruka Therapeutics by 374.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,326,893 shares of the company’s stock worth $25,730,000 after acquiring an additional 1,047,245 shares during the period. Finally, Franklin Resources Inc. purchased a new stake in shares of Oruka Therapeutics during the third quarter worth about $17,661,000. 56.44% of the stock is currently owned by institutional investors.
About Oruka Therapeutics
Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.
Featured Articles
- Five stocks we like better than Oruka Therapeutics
- How to Invest in Biotech Stocks
- Salesforce’s Hidden Strengths Could Fuel a Powerful Rebound
- Stock Market Sectors: What Are They and How Many Are There?
- 3 Stocks With Unusual Call Option Volume – What It Signals
- Consumer Staples Stocks, Explained
- Top 4 Healthcare REITs Turning Care Into Big Investor Payouts
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.